Venus Medtech VenusP-Valve transcatheter pulmonic valve replacement system granted Health Canada approval
HANGZHOU, China, Feb. 5, 2024 /PRNewswire/ -- Venus Medtech (02500. HK), a leading provider of integrated solutions for transcatheter structural heart valvular therapies inChina, announced today that, VenusP-Valve, the company's in-house developed innovative transcatheter pulmonic valve replaceme...
Venus Medtech's Exciting Innovations for Structural Heart to Be Showcased at London Valves 2023
The company will be presenting its growing pipeline of superb technologies for treating all four heart valves in its booth and at multiple events during the conference. HANGZHOU, China, Nov. 20, 2023 /PRNewswire/ -- Venus Medtech is changing how the world treats structural heart disease. The com...
VenusP-Valve granted IDE approval for clinical trial, unveiling a new chapter for Chinese valve solutions globally
HANGZHOU, China, Aug. 7, 2023 /PRNewswire/ -- Recently, Venus Medtech (Hangzhou ) Inc. ("Venus Medtech"), a leading provider of integrated solutions for transcatheter structural heart valvular therapies inChina, announced the Investigational Device Exemption (IDE) full approval for its in-house de...
Confirmatory clinical trial of Liwen RF™ ablation system in China concluded
HANGZHOU, China, March 6, 2023 /PRNewswire/ -- On March 3, Venus Medtech ( Hangzhou) Inc. (Venus Medtech, 2500.HK), trailblazer in structural heart therapies worldwide, announced that the Liwen RF™ ablation system developed by the Company has successfully enrolled one patient at West China Hospita...
Venus Medtech to showcase its structural heart treatments at London Valves 2022
The company's growing number of solutions for structural heart disease will be presented at multiple events during the conference betweenNovember 27-29 HANGZHOU, China, Nov. 25, 2022 /PRNewswire/ -- Venus Medtech is building an exciting pipeline of treatments for structural heart disease. The co...
Venus Medtech announces 2022 interim results: quality and efficiency improvement, profitability focus, rapid progress in global presence
HANGZHOU, China, Sept. 1, 2022 /PRNewswire/ -- On August 31, 2022, Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as "Venus Medtech"), a leading provider of integrated solutions for transcatheter structural heart valvular therapies inChina, announced its interim results for the s...
Qiming's Portfolio Company InventisBio Lists on STAR Market
SHANGHAI, July 25, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange. The issue price isCNY 18...
Qiming's Portfolio Company InventisBio Lists on STAR Market
SHANGHAI, July 24, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange.The issue price is CNY 18...
Qiming Venture Partners Announces Closing of Funds Totaling US$3.2 Billion
SHANGHAI, July 11, 2022 /PRNewswire/ -- Qiming Venture Partners announced today the closing of its latest funds totalingUS$3.2 billion, including USD Fund VIII atUS$2.5 billion and the first closing of RMB Fund VII at RMB 4.7 billion (or US$ 700 million). As in prior funds, Fund VIII was oversub...
First American Patient Treated with VenusP-Valve™ Under Compassionate Use
HANGZHOU, China, June 22, 2022 /PRNewswire/ -- VenusP-Valve™, an in-house developed novel medical device of Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as "Venus Medtech"), recently completed its first compassionate use atUniversity of Virginia Advanced Cardiac Valve Center in...
Qiming's Nisa Leung, Duane Kuang Named on 2022 Forbes Midas List
SHANGHAI, April 13, 2022 /PRNewswire/ – Forbes released the 2022 Midas List on April 12, a ranking of the world's top 100 venture capitalists. Nisa Leung, Managing Partner of Qiming Venture Partners, andDuane Kuang, Founding Managing Partner of Qiming Venture Partners, ranked on the list. Since ...
Venus Medtech announces 2021 annual results: pacesetter in China and breakthrough-maker worldwide
HANGZHOU, China, April 1, 2022 /PRNewswire/ -- On March 31, 2022, Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as "Venus Medtech"), a leading provider of integrated solutions for transcatheter structural heart valvular therapies inChina, announced its annual results for the yea...
Venus Medtech appoints Shakeel Osman as Senior VP of Sales Europe to drive commercialization of TPVR system
HANGZHOU, China, March 18, 2022 /PRNewswire/ -- On March 18th, 2022, Venus Medtech (Hangzhou) Inc. ("Venus Medtech", 2500.HK), a leading provider of integrated solutions for structural heart disease inChina, announced the appointment ofShakeel Osman as Senior Vice President of Sales Europe, resp...
Venus Medtech Concludes Acquisition of 100% Equity Interest in Cardiovalve
HANGZHOU, China, Jan. 26, 2022 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus MedTech, 2500.HK), a leading, innovative Chinese structural heart disease treatment company, announced its acquisition of 100% equity interest in Cardiovalve Ltd. (Cardiovalve), a pioneering transcatheter mitral a...
Venus Medtech Acquires Cardiovalve to Optimize its Innovative Products Pipeline of Mitral and Tricuspid Valve Replacement
HANGZHOU, China, Dec. 8, 2021 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus MedTech, 2500.HK), a leading, innovative Chinese structural heart disease treatment company, announced its acquisition of Cardiovalve Ltd. (Cardiovalve), a pioneering transcatheter mitral and tricuspid valve treatm...
Venus Medtech Appoints Professor Martin B. Leon as Global Principal Investigator of Its New-Generation RDN System
HANGZHOU, China, July 28, 2021 /PRNewswire/ -- On July 27, 2021, Venus Medtech ( Hangzhou) Inc. ("Venus Medtech") (stock code: 2500.HK), a leading provider of comprehensive interventional heart valve therapy solutions inChina, and its controlling subsidiary Renaly Ltd., announced that Professor...
Venus Medtech Taps into Surgical Heart Valve Market by Cooperating with Haoyue Group to Develop the Business of High-end Biomaterial Medical Devices
HANGZHOU, China, Sept. 10, 2020 /PRNewswire/ -- The leading transcatheter heart valve medical device player inChina - Venus Medtech (Hangzhou) Inc. ("Venus Medtech" or the "Company", together with its subsidiaries, the "Group", stock code: 2500) andJilin Changchun Haoyue Halal Meat Co., Ltd ("Hao...
Venus Medtech to Partner with Pi-Cardia to Bring its Leaflex(TM) Aortic Valve Technology to China
HANGZHOU, China and REHOVOT, Israel, July 14, 2020 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (stock code: 2500.HK), the leading transcatheter heart valve medical device player in China, and Pi-Cardia Ltd., a global leader in the development of non-implant catheter-based solutions for treating...
Venus Medtech and Opus Medical Therapies, LLC Announce Partnership for Transcatheter Mitral Valve Replacement (TMVR) and Transcatheter Tricuspid Valve Replacement (TTVR) in Greater China Market
HANGZHOU, China and ATLANTA, May 2, 2020 /PRNewswire/ -- Venus Medtech (Hangzhou ) Inc. ("Venus Medtech" or the "Company", together with its subsidiaries, the "Group", stock code: 2500), the leading Chinese transcatheter heart valve company and Opus Medical Therapies, LLC, a medical device company...
Venus Medtech Announces the Addition of Two Cardiovascular Experts to Their Advisory Team
HANGZHOU, China, Jan. 20, 2020 /PRNewswire/ -- The leading transcatheter heart valve medical device player inChina - Venus Medtech (Hangzhou) Inc. ("Venus Medtech" or the "Company", stock code: 2500.HK), today is pleased to announce the appointment of two new cardiovascular experts to its advisor...
